GlassScriptPhysician profile
Arrey I Eyongherok
NPI 1205343936
$718.10
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.89 · 2022: $139 · 2023: $195 · 2024: $181 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $139.29 | 2021-2022 | |
| Indivior INC. | $133.92 | 2021-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $105.02 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Braeburn INC. | $81.12 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $65.87 | 2023 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $45.24 | 2025 | |
| Abbvie INC. | $43.09 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.66 | 2023-2024 | Caplyta |
| Neuronetics, INC. | $27.70 | 2023 | Neurostar Tms Therapy System |
| Alkermes, INC. | $21.73 | 2024 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $12.82 | 2021 | |
| Noven Therapeutics, LLC | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arrey Eyongherok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.